Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ECE1 | P42892 | 3/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.34 |
| ▸ | GRIK1 | P39086 | 3/20 | 0.34 |
| ▸ | SLC7A5 | Q01650 | 2/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | BLM | P54132 | 1/20 | 0.33 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.31 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.31 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.31 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.30 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16682790 | 1.00 | ECE1 (0.37) | ECE1ALDH1A1MAPTPTGS1GRIK1 | |
| SCHEMBL20363304 | 0.86 | ECE1 (0.33) | ECE1ALDH1A1MAPTPTGS1GRIK1 | |
| SCHEMBL8529151 | 0.83 | ECE1 (0.33) | ECE1ALDH1A1 | |
| SCHEMBL8529154 | 0.83 | ECE1 (0.33) | ECE1ALDH1A1 | |
| SCHEMBL8529461 | 0.83 | ECE1 (0.33) | ECE1ALDH1A1 | |
| SCHEMBL8853350 | 0.80 | TDP1 (0.43) | MAPTGRIK1BLMGABRR1 | |
| SCHEMBL1941444 | 0.80 | TDP1 (0.43) | MAPTGRIK1BLMGABRR1 | |
| SCHEMBL1941442 | 0.80 | TDP1 (0.43) | MAPTGRIK1BLMGABRR1 | |
| SCHEMBL10034713 | 0.79 | ECE1 (0.34) | ECE1 | |
| SCHEMBL1705139 | 0.79 | ECE1 (0.34) | ECE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10654815-B2 | Urea compound and preparation method and application thereof | SHENZHEN CHIPSCREEN BIOSCIENCES CO., LTD. (CN) | 2020-05-19 | — | — | US | disclosed |
| US-20160346402-A1 | ANTIBODY DRUG CONJUGATES (ADCS) WITH KINESIN SPINDEL PROTEIN (KSP) | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-12-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10654815-B2 | Urea compound and preparation method and application thereof | PDCD1, CD274, PDCD10 | ECE1 1181/4885ALDH1A1 422/4885MAPT 666/4885 |
| US-20160346402-A1 | ANTIBODY DRUG CONJUGATES (ADCS) WITH KINESIN SPINDEL PROTEIN (KSP) | KIF5B, KIF23, KIF2C | ECE1 1833/4885ALDH1A1 924/4885MAPT 127/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.